Eruptive Keratoacanthomas Associated With Pembrolizumab Therapy
- 1 July 2017
- journal article
- case report
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 153 (7) , 694-697
Abstract
Importance To our knowledge, there have been no previous reports of eruptive keratoacanthomas (KAs) in patients receiving pembrolizumab. Objective To report the cases of 3 consecutive patients with pembrolizumab-induced eruptive KAs and their management. Design, Setting, and Participants Case report study of 3 patients from 2 centers with pembrolizumab-treated cancer who all developed eruptive KAs. Interventions All 3 patients had AK treatment with clobetasol ointment and intralesional triamcinolone; 2 patients also underwent open superficial cryosurgery. Results Three consecutive patients with cancer, 2 men and 1 woman (median age, 83 years; range 77-91 years), experienced pembrolizumab-associated eruptive KAs. All patients presented with a sudden onset of multiple lesions on sun-exposed areas of their extremities after a median of 13 months (range, 4-18 months) of pembrolizumab therapy. On lesional biopsy, a lichenoid infiltrate was observed in the underlying dermis, predominantly composed of CD3+T cells, scattered CD20+B cells, and relatively few PD-1+(programmed cell death 1–positive) T cells, an immunophenotypic pattern also observed in other cases of anti–PD-1–induced lichenoid dermatitis. Patients were treated with clobetasol ointment and intralesional triamcinolone, alone or in combination with open superficial cryosurgery. All KAs resolved in all patients, and no new lesions occurred during close follow-up. Pembrolizumab treatment was continued without disruption in all 3 cases, and all patients had complete responses of their primary cancers. Conclusions and Relevance Pembrolizumab is used in advanced melanoma, advanced non–small-cell lung cancer, and in head and neck cancer. A variety of dermatologic immune-related adverse events including maculopapular eruption, lichenoid reactions, pruritus, and vitiligo have been described. This case series demonstrates that pembrolizumab therapy may also be associated with eruptive KAs with characteristic dermal inflammation, which improved with corticosteroid treatment (topical and intralesional) alone or in combination with cryosurgery, allowing patients to continue therapy with pembrolizumab.Keywords
This publication has 16 references indexed in Scilit:
- Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with OutcomesClinical Cancer Research, 2016
- Eruptive Keratoacanthomas Associated With LeflunomideJAMA Dermatology, 2016
- Pembrolizumab Cutaneous Adverse Events and Their Association With Disease ProgressionJAMA Dermatology, 2015
- Use of cryobiopsy in dermatological practiceJournal of the American Academy of Dermatology, 2015
- Cutaneous keratoacanthomas/squamous cell carcinomas associated with neutralization of transforming growth factor β by the monoclonal antibody fresolimumab (GC1008)Cancer Immunology, Immunotherapy, 2015
- Lichenoid Dermatitis in Three Patients with Metastatic Melanoma Treated with Anti–PD-1 TherapyCancer Immunology Research, 2015
- Clinico‐morphological features of BRAF inhibition–induced proliferative skin lesions in cancer patientsCancer, 2014
- Keratoacanthomas arising in association with prurigo nodules in pruritic, actinically damaged skinJournal of the American Academy of Dermatology, 2013
- Generalized eruptive keratoacanthoma: proposed diagnostic criteria and therapeutic evaluationJournal of the European Academy of Dermatology and Venereology, 2013
- New Onset of Keratoacanthomas After Vismodegib Treatment for Locally Advanced Basal Cell Carcinomas: A Report of 2 CasesJAMA Dermatology, 2013